SPL

1.02%

9.7¢ starpharma holdings limited

DEP always first, page-19

First 19 Last

Share
Profile

Follow
chrisnj

2,085 Posts.

307

15/03/19

12:01

Post #: 37773218
Share

Originally posted by jazzapat: ↑

hi Chris, I don’t think the antibiotic dosing for the second phase III trial is the issue. This trial design was agreed with the FDA and supports the claim for the prevention of recurrent BV. E.g. the antibiotics treated the BV and vivagel prevented recurance in a population who suffered from rBV. Primary and secondary points all met. This supports the claim for prevention after treatment.

data from the first phase III trial was largely used (in my opinion) to support the BV treatment claim. This is the trial that initially missed the primary end points at TOC but was statistically signicant at EOT. SPL subsequently indicated that it had passed the primary end points at revised TOC, but I do not recall seeing detailed data on Testing of Cure for these revised / shortened time periods.

Hence, it appears that we can assume vivagel
- prevents recurance of rBV after it has been treated with antiobiotics
- treats bv up until end of treatment / whilst it is being applied
- but that BV returns after around 3 weeks after treatment ceases (why we failed the first phase III primary end points).

My view is that we will work with the FDA to get approval of some sort with limited claims but that we will need more data for stronger claims around treatment. There are many products available now for eczema as an example that reduce the symptoms and prevent / delay recurance or provide temporary relief etc. I think we will see a similar outcome here.

The above is is all speculation just like Stockrocks assertion that we will definitely need another clinical trial.

Regardless, SPL needs to focus on preparing as best as possible for this FDA meeting and leveraging as much local FDA expertise they can. They need to launce in other regions ASAP and get more DEP programs into the clinic to stop the share price decline.

Expand

With your summary jazzapat you suggest that antibiotics is part of the treatment regime whereas it has always been claimed by SPL that they are dispensing with the need to use them.

Also l thought the 2nd trial was for both treatment and prevention of recurrence??

SPL Price at posting: $1.00 Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

IMA

Issues emerging as Australian companies tackle critical minerals challenge

SHN

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NWH

NRW Holdings inks $109M deal with BHP for works at Jimblebar

CXU

Cauldron Energy reports "excellent" uranium assays in latest drill run

TIG

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

RAG

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

A3D

Defence MOU for propulsion systems pushes Aurora Lab shares higher

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

There are more pages in this discussion • 3 more messages in this thread...

First 19 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 9.7¢		Change -0.001(1.02%)		Mkt cap ! $40.48M

Open	High	Low	Value	Volume
9.6¢	10.0¢	9.6¢	$5.703K	58.16K

Buyers (Bids)

No.	Vol.	Price($)
1	100000	9.6¢

Sellers (Offers)

Price($)	Vol.	No.
9.8¢	20000	1

View Market Depth

No.	Vol.	Price($)
2	8325	0.095
3	160000	0.094
2	9659	0.093
2	134306	0.092
1	11000	0.091

Price($)	Vol.	No.
0.098	20000	1
0.100	4000	1
0.105	143620	3
0.110	198286	10
0.115	103400	3

Last trade - 15.41pm 11/10/2024 (20 minute delay)

SPL (ASX) Chart

DEP always first, page-19

Issues emerging as Australian companies tackle critical minerals challenge

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Cauldron Energy reports "excellent" uranium assays in latest drill run

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Defence MOU for propulsion systems pushes Aurora Lab shares higher

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

DEP always first, page-19

Top Stories

Issues emerging as Australian companies tackle critical minerals challenge

Sunshine Metals kicks off copper gold drilling at Truncheon; Highway East targets

NRW Holdings inks $109M deal with BHP for works at Jimblebar

Cauldron Energy reports "excellent" uranium assays in latest drill run

Tigers Realm's US$49M sale of Russian assets – to a Kremlin-adjacent billionaire – set to go ahead

Ragnar impressed by 11.55 metre pegmatite in Sweden, anticipating further mineralisation

Week 41 Wrap: HotCopper asks “Back to Mongolia?” for Elixir; US CPI comes in at 2.4%; eyes still on China

ASX Market Open: ASX200 to open flattish after Wall Street weakens on hot US inflation data | October 11, 2024

Defence MOU for propulsion systems pushes Aurora Lab shares higher

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News